Compare POWI & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POWI | NRIX |
|---|---|---|
| Founded | 1988 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.8B |
| IPO Year | 1997 | 2020 |
| Metric | POWI | NRIX |
|---|---|---|
| Price | $40.08 | $15.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 14 |
| Target Price | ★ $74.00 | $33.50 |
| AVG Volume (30 Days) | 746.3K | ★ 3.3M |
| Earning Date | 11-04-2026 | 10-12-2026 |
| Dividend Yield | ★ 2.21% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.56 | ★ 3.26 |
| Revenue | ★ $443,504,000.00 | $76,987,000.00 |
| Revenue This Year | $7.70 | $786.93 |
| Revenue Next Year | $13.15 | N/A |
| P/E Ratio | $203.48 | ★ $4.89 |
| Revenue Growth | 5.86 | ★ 99.31 |
| 52 Week Low | $30.86 | $12.01 |
| 52 Week High | $91.18 | $28.23 |
| Indicator | POWI | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 33.07 | 21.32 |
| Support Level | N/A | $14.63 |
| Resistance Level | $49.51 | $17.47 |
| Average True Range (ATR) | 2.53 | 1.29 |
| MACD | -0.57 | -1.25 |
| Stochastic Oscillator | 14.84 | 3.03 |
Power Integrations Inc designs, develops, and markets analog and mixed-signal integrated circuits (ICs) and other electronic components and circuitry used in high-voltage power conversion. Products are used in power converters that convert electricity from a high-voltage source to the type of power required for a specified downstream use. Products are used in electronic products including mobile phones, computing and networking equipment, appliances, electronic utility meters, battery-powered tools, industrial controls, home automation, or Internet of Things applications such as networked thermostats, power strips, and security devices. Geographically, the company generates maximum revenue from China and Hong Kong.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.